Article
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
PloS one - 1 Jan 2014
Liang Wenhua, Wu Xuan, Fang Wenfeng, Zhao Yuanyuan, Yang Yunpeng, Hu Zhihuang, Xue Cong, Zhang Jing, Zhang Jianwei, Ma Yuxiang, Zhou Ting, Yan Yue, Hou Xue, Qin Tao, Dinglin Xiaoxiao, Tian Ying, Huang Peiyu, Huang Yan, Zhao Hongyun, Zhang Li
Abstract excerpt
BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs in mutated populations have been reported, which provides room for indirect and integrated comparisons. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.